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Islets encapsulated in immunoprotective microcapsules are being proposed as an alter-
native for insulin therapy for treatment of type 1 diabetes. Many materials for producing
microcapsules have been proposed but only alginate does currently qualify as ready for
clinical application. However, many different alginate-based capsule systems do exist. A
pitfall in the field is that these systems are applied without a targeted strategy with vary-
ing degrees of success as a consequence. In the current review, the different properties
of alginate-based systems are reviewed in view of future application in humans. The use
of allogeneic and xenogeneic islet sources are discussed with acknowledging the differ-
ent degrees of immune protection the encapsulation system should supply. Also issues
such as oxygen supply and the role of danger associated molecular patterns (DAMPS) in
immune activation are being reviewed. A common property of the encapsulation systems
is that alginates for medical application should have an extreme high degree of purity and
lack pathogen-associated molecular patterns (PAMPs) to avoid activation of the recipient’s
immune system. Up to now, non-inflammatory alginates are only produced on a lab-scale
and are not yet commercially available. This is a major pitfall on the route to human appli-
cation. Also the lack of predictive pre-clinical models is a burden. The principle differences
between relevant innate and adaptive immune responses in humans and other species are
reviewed. Especially, the extreme differences between the immune system of non-human
primates and humans are cumbersome as non-human primates may not be predictive of
the immune responses in humans, as opposed to the popular belief of regulatory agen-
cies. Current insight is that although the technology is versatile major research efforts are
required for identifying the mechanical, immunological, and physico-chemical requirements
that alginate-based capsules should meet for successful human application.
Keywords: alginate, purification, microencapsulation, PAMPs, DAMPs, innate immune activation, non-human
models
INTRODUCTION
Patients suffering from diabetes would benefit from an endocrine
insulin source that regulates glucose metabolism on a minute-
to-minute level. A minute-to-minute regulation avoids frequent
episodes of hyperglycemia and hypoglycemia as with exogenous
insulin therapy, and therefore, improves the quality of life (Vaith-
ilingam and Tuch, 2011). Therapeutically, there are two options
for transplanting an endocrine insulin source, i.e., transplanta-
tion of the whole pancreas or transplantation of only pancre-
atic islets. Pancreas transplantation is currently being performed
in almost all major surgical centers but requires major surgery,
life-long immunosuppression, and is associated with morbidity
(Vaithilingam and Tuch, 2011). For these reasons, pancreas trans-
plantation is only applied in diabetics that suffer from end-stage
renal failure and receive a combined kidney and pancreas as a
life-saving intervention.
Transplantation of pancreatic islets is not associated with major
surgery as it involves a small amount of tissue and is, therefore,
considered to be a better option for diabetic patients (Mittal et al.,
2014). Another advantage of transplantation of pancreatic islets
is their size. Islets are small organs of 50–350µm that can be
manipulated in order to prevent rejection. Currently, however,
islet-transplantation requires chronic application of immunosup-
pressive therapy that restricts the use of this technique (Ryan
et al., 2005; Figliuzzi et al., 2014). Up to now, only patients with
unstable metabolic control, repeated severe episodes of hypo-
glycemia and hypoglycemic unawareness, or those with rapidly
progressive diabetes-associated complications are eligible for islet-
transplantation in most centers (Vantyghem et al., 2014). This
will change with new technical approaches that minimize or
completely prevent rejection of islets.
Application of immunosuppressive medication can be avoided
when islets are enveloped in immunoprotective membranes. These
membranes protect pancreatic islets from the effector side of the
host immune system and thus prevent rejection. This encap-
sulation in immunoprotective membranes can be done in two
geometries, i.e., macro- and microcapsules. In macrocapsules, the
cells are packed in relatively large diffusion chambers. The walls of
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these chambers are semipermeable. Macrocapsules can be applied
as intra- or extravascular devices. In intravascular approaches, the
cells are seeded outside of artificial capillaries and connected to the
blood stream. The advantage of intravascular devices is close con-
tact of cells with the blood stream implying the fast exchange of
glucose and insulin. A major disadvantage, however, is that throm-
bosis may occur. This makes the use of life-long anti-coagulation
therapy a requirement (Uludag et al., 2000; de Vos et al., 2006a;
Krishnamurthy and Gimi, 2011; Nafea et al., 2011; Vaithilingam
and Tuch, 2011). For diabetic patients, this risk of thrombosis
makes intravascular devices an unacceptable alternative for insulin
therapy. For this reason, most groups currently focus on extravas-
cular devices, in which pancreatic islets are enveloped within
semipermeable diffusion chambers and implanted under the skin
or in the peritoneal cavity without direct vascular access. The tech-
nology is associated with minor surgery and allows replacement
of the graft when the islets have to be substituted.
Microcapsules are very different in concept from macrocap-
sules. Within this technology, islets are individually packed in their
own, individual capsule. An advantage over macrocapsules is that
the microcapsules have an optimal surface to volume ratio, which
implies a faster exchange of glucose, insulin, and nutrients (Uludag
et al., 2000; Krishnamurthy and Gimi, 2011; Nafea et al., 2011;
Vaithilingam and Tuch, 2011). For this reason, microencapsulation
is preferred over macrocapsules as nutrient supply is more read-
ily available in microcapsules than in macrocapsules. Especially,
oxygen diffusion is an issue. Islets require relative high amounts
of oxygen for both function and survival. Oxygen availability to
the islets depends more on the O2 partial pressure (pO2) in the
transplantation site rather than on O2 concentrations such as with
other nutrient (Johnson et al., 2011; Colton, 2014) (Figure 1).
Microcapsules, however, can be obtained in many different
forms, sizes, composition, and with different permeability (de Vos
et al., 2014). Some use cation-crosslinked concepts while others
use multiple layer systems (Lebedeva et al., 2004; de Vos et al.,
2009; Dufrane and Gianello, 2012). The capsules are being used
for allogeneic sources as well as for xenogeneic sources without
taking into account that for xenogeneic sources other require-
ments have to be met than those for allogeneic sources. For
FIGURE 1 |The three different categories of encapsulation devices used
for immunoisolation of islets. Comparison between size and diffusion
rate of nutrients and oxygen through the semipermeable membranes.
protection of allogeneic tissue, the prevention of cell–cell con-
tact between donor-islets and immune-cells is considered to be
sufficient to prevent rejection (Duvivier-Kali et al., 2001). Simple
systems such as cation-alginate capsules (Mazzitelli et al., 2008)
can, therefore, be effective in protection for allogeneic responses.
However, when the donor-recipient histocompatibility becomes
more discordant such as with xenografts other processes come
into play (Anderson and Kirk, 2013). When highly immunoreac-
tive epitopes on xenogenic islets diffuse out of capsules, such as
galactosyl residues, they may react with naturally occurring (anti-
Gal) and non-Gal IgM antibodies. The previous may activate the
classical complement pathway and may lead to neutrophil infil-
tration (Dufrane and Gianello, 2012) and release of deleterious
cytokines that can pass the capsule membrane. IgM is not able
to pass most of the capsule’s membrane but the IgM-mediated
humoral reaction against xenogeneic epitopes can also induce
the typical delayed-type hypersensitivity response associated with
xenografts (Dufrane and Gianello, 2012), which leads to signifi-
cant production of even smaller cytokines that can freely pass the
membrane. These immunological processes in association with
the type of microcapsule system will be discussed in the present
review in view of future application for protection of grafts for
small cytokines produced in several immunological responses that
occur after implantation of microencapsulated pancreatic islets.
POLYMERS FOR MICROENCAPSULATION
Polymers applied for microcapsules should meet a number of
requirements, they should not negatively impact the viability of
encapsulated cells, be flexible, soft, mechanically stable, allow dif-
fusion of molecules of interest, and highly biocompatible to reduce
host immune responses (Figure 2). The polymers that have been
applied are derived from synthetic or natural sources. The most
commonly used sources have recently been reviewed and are
FIGURE 2 | Principle of immunoisolation by a microcapsule. The
semipermeable membrane allows the diffusion of molecules such as
nutrients, glucose, oxygen, and insulin while protecting the graft from the
effector molecules of the immune system of the host.
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poly(ethylene glycol), polyvinyl alcohol, polyurethane, polyether-
sulfone, polypropylene, sodium polystyrene sulfate, polyacrylate,
agarose, chitosan, cellulose, collagen, xanthan, and alginate (de Vos
et al., 2014). The current consensus is that only alginate has been
studied in sufficient detail to qualify as safe for human application
(de Vos et al., 2014). Other polymers might become available in
the future but have not been sufficiently studied in terms of com-
patibility with functional survival with the enveloped tissue and
the host. Also diffusion characteristics of essential immunologi-
cal molecules and nutrients have been poorly studied with other
polymers. Therefore, when describing the immunological issues
in the next sections and the different approaches of encapsulation,
we will mainly concentrate on alginate as the core biomaterial. We
would like to emphasize, however, that these are all generic issues
that also other systems have to take into account.
DIFFERENT ALGINATES RESULTS IN DIFFERENT CAPSULE
PROPERTIES
In 1881, Stanford was the first to describe alginate (Draget, 2000).
Alginate is an unbranched binary copolymer of 1–4 linked β-d-
mannuronic acid (M) and α-l-guluronic acid (G) (Figure 3) that
can be isolated from algae like Laminaria hyperborea, Macrocys-
tis pyrifera, Laminaria digitata, Ascophyllum nodosum, Laminaria
japonica, Eclonia maxima, Lessonia nigrescens, Durvillea antarc-
tica, and Sargassum spp. It can also be found as a polysaccharide
in bacteria such as Azotobacter vinelandii and Pseudomonades
(Wee and Gombotz, 1998; Draget, 2000). In principle, alginate
is built of G-G blocks, G-M blocks, and M-M blocks. These
blocks can be found in different ratios and in different molec-
ular weights in alginate preparations, which gives them different
physical and chemical characteristics (Ostgaard et al., 1993; de
Vos et al., 2014). There are numerous types of alginates as a
consequence. In the encapsulation-field, alginates are classified
as high-G alginate, intermediate-G alginate, and low-G alginate.
For forming microcapsules, alginates are usually collected in a
solution containing high concentrations of cations. This leads
FIGURE 3 | Chemical structure of alginate. Linear block polymers of
β-D-mannuronate (M) and -L-guluronate (G) with a variation in composition
and sequential arrangements.
to gel-formation. During this process, the uronic acid blocks in
alginate bind to cations, like in an egg box model (Figure 4).
The constitutive uronic molecules in alginate create zones in the
gel that are interconnected. This provides rigidity. However, the
rigidity and elasticity of the gels is not only determined by the
type of alginate but also by the type of cation applied. This is
influenced by the chemical properties of the cation applied such
as atomic number, ionic radius, ionic strength, association con-
stant, and chemical affinity toward alginate. The binding of ions
is highly selective and the affinity strongly depends on the algi-
nate composition and sequence. More specifically, Ba2+ binds to
G-G and M-M blocks, Ca2+ binds to G-G and M-G blocks, and
Sr2+ binds to G-G blocks solely (Figure 5). The amount of blocks
determines the cross-linking degree, and therefore, also the rigid-
ity and strength of the capsule. Also the permeability and, thus,
the immunoprotective properties are determined by the type and
concentration of the alginates in combination with the type of
cation. The reason to mention and discuss these items explicitly
is that many researchers in the field are not aware of these essen-
tial factors for capsule performance. This lack of awareness has
led to the current extreme lab-to-lab variations in reported bio-
compatibility and immunoprotective properties of alginate-based
capsules. This is a true obstacle for progress in the field as side-
by-side comparison of data-sets is nearly impossible (de Vos et al.,
2009, 2012; Mallett and Korbutt, 2009; Tam et al., 2011b).
POLYMERS MIGHT CONTAIN CONTAMINATIONS
To protect ourselves against harmful bacteria, viruses, and other
microbes the human immunological defense system has developed
two powerful weapons: the innate immune system and the adap-
tive immune system. The innate immune response is the first to act
when uninvited hazardous elements invade our tissue. It is armed
with powerful tools to attack invaders and to heal damaged tissue.
This innate response is predominantly involved in foreign body
responses. It reacts virtually in the same fashion against all type
of foreigners and has almost no flexibility or memory. The adap-
tive immune response is more versatile but slow. It customizes its
response to particular invaders and builds up an immunological
memory after which life-long protection occurs against the for-
eign invader (Kawai and Akira, 2010; Mantovani et al., 2011; Netea
et al., 2011; Kumar et al., 2013). The fast majority of encapsulation
systems are designed to protect the tissue against the effects of
the adaptive immune system (Jones et al., 2004). The relation and
responses of the adaptive immune system have been reviewed in
other papers (Franz et al., 2011; Mantovani et al., 2011; Oberbarn-
scheidt et al., 2011). The effect of the innate immune response on
functional survival has not been reviewed intensively and has to
our opinion not received the necessary attention.
It is well recognized that when preparing alginate-based cap-
sules with polymers the materials applied should lack any compo-
nent that might provoke an innate immune system. The impor-
tance of applying true pure polymers has been demonstrated
with alginate (Paredes-Juarez et al., 2013). It has been shown that
crude alginates contain many components that provoke strong
inflammatory responses leading to overgrowth of the capsule with
immune-cells and fibroblasts (Figure 6). This overgrowth inter-
feres with the exchange of nutrients and with necrosis of the
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FIGURE 4 | Gelation process of alginate. Alginate dropped from an air droplet generator into a CaCl2 solution to form a non-homogenous microcapsule in an
“egg” formation. Gels are formed by cross-linking of alginate-polymers with calcium ions between G-G and M-G-blocks.
FIGURE 5 | Binding of Sr2+, Ca2+, and Ba2+ to alginate. Cross linking between ions and G-G and M-M or G-M blocks of alginate occurs in specific
conformations, (A) Sr2+ binds to G-G blocks solely, (B) Ca2+ binds to G-G and M-G blocks, and (C) Ba2+ binds to G-G and M-M blocks.
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FIGURE 6 | Microcapsules produced with purified or crude alginate.
Use of crude alginate or alginates containing PAMPs promotes after
implantation activation of the host immune system with recruitment of
immune-cells as a consequence. Necrosis of the islet-cells is an inevitable
consequence.
islet-cells as a consequence. Removal of the immunogenic compo-
nents from alginate has for these reasons been the focus of many
research reports, but it is not a straightforward task and is still a
struggle for many groups (de Vos et al., 1997; Kendall et al., 2004;
Tam et al., 2006; Mallett and Korbutt, 2009; Ménard et al., 2010;
Calafiore and Basta, 2014; Steele et al., 2014).
Alginates are isolated from natural sources and are cont-
aminated with immunogenic substances during the industrial
processes used for extraction. Impurities that have to be removed
are molecules such as polyphenols, endotoxins, and proteins (de
Vos et al., 2006b; Paredes-Juarez et al., 2014). By applying purifi-
cation, a reduction of the host-response against the capsules can
be accomplished but a persistent obstacle remains. Graft survival
is never pertinent and varies considerable from several weeks to
months (de Vos et al., 2006b).
It has become more and more recognized that immunogenic
components in the polymers do not necessarily have to lead to
overgrowth of the capsules. In almost all encapsulation systems,
hydrogels are being applied, which are not readily compatible with
cell adhesion. Immune-cells will only adhere when significant pro-
tein adsorption occurs or when anchoring points are available on
capsule surfaces (de Vos et al., 2006b). In most cases, however, the
inflammatory response will occur in the direct vicinity and not on
the capsule’s surface (de Vos et al., 2002). It has been shown by
our group (de Vos et al., 2002) that in the first days after implanta-
tion in rats significant amounts of immune-cells can be found in
between the capsules but not on the surface of the capsules. This
cell-infiltrate is composed of macrophages in different activation
stadia, granulocytes, and basophiles (de Vos et al., 2002). These
cells produce large quantities of cytokines, chemokines, and other
deleterious bioactive molecules that can diffuse through most of
the different types of capsules and kill islet-cells. Although the
immune-cells have disappeared after 2 weeks, the reported loss of
islets can be up to as much as 60% of the graft (de Vos et al., 2014).
This all occurs without any adhesion of the cells to the capsule
surface and can be missed if the responses against the graft are
studied after period longer than 2 weeks (de Vos et al., 2002).
In search of factors contributing to this response, it was found
that many alginates that are classified as pure and often recom-
mended for human application still contain elements that provoke
or contribute to the above described responses (Paredes-Juarez
et al., 2013, 2014). Up to now these molecules were being addressed
as endotoxins. The most commonly known endotoxin is LPS, but
there are other molecules that also have to be qualified as endotox-
ins and which are responsible for many of the above-mentioned
responses as will be outlined below. In a recent study, we have
shown that commercially available “ultra-pure” alginates still con-
tain lipoteichoic acid and sometimes even LPS (Paredes-Juarez
et al., 2014).
PATHOGEN-ASSOCIATED MOLECULAR PATTERNS IN
POLYMER PREPARATIONS
A different word for endotoxins is pathogen-associated molecu-
lar patterns (PAMPs). In immunology-related research the term
PAMPs is much more often used than endotoxin. The role of
PAMPs in initiation of immune responses has been subject of
intensive studies in the past decade and emerging new insight
has been generated in how PAMPs induce activation of the
innate immune system. The role of alginate-derived PAMPs in
the responses against capsules in the immediate period after
transplantation will be discussed in the next sections.
Cells of the innate immune system that are involved in the reac-
tion against capsules express innate receptors or sensors known as
pattern-recognition receptors (PRRs) that can recognize evolu-
tionary conserved molecules shared by pathogens (Kumar et al.,
2013) but not present on mammalian cells (Oberbarnscheidt
et al., 2011) (Figure 7). The PRRs are formed by receptor-families
such as NOD-like receptors (NLRs), RIG-I-like receptors (RLRs),
C-type lectin receptors (CLRs), DNA-sensing molecules, and Toll-
like receptors (TLRs) (Hedayat et al., 2011; Kumar et al., 2013).
The latter, the TLRs are well-known (Kawai and Akira, 2010, 2011;
Kumar et al., 2013) and involved in responses against alginate-
based capsules (Flo et al., 2002; Iwamoto et al., 2005; Paredes-
Juarez et al., 2013). In humans, 10 different members of the TLRs
family have been identified (Kumar et al., 2013) with specific cellu-
lar location and functions (Table 1). Mechanistically, most of TLRs
interact with the coupling protein myeloid differentiation primary
response gene 88 (MyD88), which leads to an internal signal-
ing cascade that induces translocation of the transcription factor
nuclear κB (NF-κB) from the cytoplasm to the nucleus (Pearl et al.,
2011). Only two human TLR can signal in a MyD88 indepen-
dent fashion, which are TLR3 that use the TIR domain-containing
adapter inducing interferon-beta (TRIF), and TLR4 that can sig-
nal via TRIF or MyD88 (Pearl et al., 2011). In a recent study,
we have shown that crude alginates contain flagellin, lipoteichoic
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FIGURE 7 | PAMP and DAMP release from microencapsulated islets.
Impurities like pathogen-associated molecular patterns (PAMPs) in
alginate can bind to pattern-recognition receptors (PRRs) such as Toll-like
receptors (TLRs) on cells of immune system. This leads to release of
cytokines, chemokines, chemotaxis, with graft failure as the ultimate
consequence. Encapsulated islets under stress, release molecules
required for cellular homeostasis but in the extracellular space act like
danger or damage-associated molecular patterns (DAMPs). DAMPs can
also bind to PRRs activating both the innate and adaptive immune
system in the host.
acid, and peptidoglycans and that they cannot easily be removed
(Paredes-Juarez et al., 2013, 2014). After purification alginates still
contain lipoteichoic acid and some sources even LPS (Paredes-
Juarez et al., 2014). All these molecules are recognized by TLRs
as PAMPs (Table 1). When present in alginate, this will always
lead to immune activation with cytokine release as a consequence
(Paredes-Juarez et al., 2013, 2014). Most of these cytokines are
small enough to pass the capsule membrane and will lead to cell-
death (Juste et al., 2005; Nafea et al., 2011; Dufrane and Gianello,
2012). It should be mentioned that not only PAMPs but also small
molecular poly-M residues should be removed. Poly-M has been
shown to be a potent activator of TLR2 and 4 (Flo et al., 2002).
DANGER ASSOCIATED MOLECULAR PATTERNS FROM
ENCAPSULATED CELLS
As the consequence of the response described above, a significant
portion of the islet-cells will die. However, more responses will
occur in the immediate post-transplantation period that will lead
to cell-death in the current encapsulation systems (Figure 7).
The implantation of grafts requires the application of surgery.
Although, this is usually minor surgery, it still leads to a tissue
repair response (de Vos et al., 2006b). A tissue repair response
involves the release of essential bioactive wound healing promot-
ing proteins such as histamine and fibronectin. The molecules
prevent growth of bacteria and facilitate influx to the site of granu-
locytes, basophiles, and finally endothelial cells. How this response
is modulated by the presence of the PAMPs in alginate is unknown
but it is recognized that this response also contributes to loss of
islet-cells (de Vos et al., 2006b). At the same time islet-cells start to
produce islet-derived cytokines such as MCP-1 that attract even
more immune-cells to the transplantation site. Dead cells in the
capsule are the inevitable consequence.
Pattern-recognition receptors not only recognize PAMPs, but
also intracellular components derived from dying cells in the cap-
sules. These intracellular components function in a normal healthy
organ as alarm signals that alert other cells of damage and promote
restoration or healing caused by damage (Daly et al., 2012). These
molecules are called danger or damage-associated molecular pat-
terns (DAMPs) (Bianchi, 2007; Kono and Rock, 2008). DAMPs
are well studied in aseptic or sterile inflammation (Hoque et al.,
2012). This is an inflammation cascade not evoked by pathogens
but induced by dying cell components that are recognized by
PRRs, mainly via TLRs. Among these alarming molecules is high-
mobility group box 1 protein (HMGB1) that in normal conditions
plays a role in the winding of DNA and promotes assembly of pro-
teins (Castiglioni et al., 2011; Daly et al., 2012). Another example
of a DAMP that is involved in failures in clinical transplantation
is heat shock protein 70 (HSP70). When it comes in the extracel-
lular milieu HSP70 promotes recruitment of immune-cells (Garg
et al., 2010; Piccinini and Midwood, 2010; Land, 2011). Other
molecules that are studied and have been identified during sterile
inflammation are uric acid and DNA (Rosin and Okusa, 2011).
Currently, in transplantation-research, it becomes more and more
recognized that DAMPs play a crucial role in the responses against
grafts (Rosin and Okusa, 2011) and probably also plays a role in
the responses against encapsulated islet grafts (de Vos et al., 2014).
DESIGN OF IMMUNOPROTECTIVE MICROCAPSULES
As mentioned before, microcapsules have been designed to protect
the enveloped cells against immune cell-donor cell interactions
and high-molecular weight effector molecules of the adaptive
immune system such as immunoglobulins and complement fac-
tors (Nafea et al., 2011). The capsules usually have a permeability
that allow for the entry of molecules below 100 kDa and allow
entry of large essential nutrient chaperons such as transferrin and
lipid carriers (de Vos et al., 1997; Jones et al., 2004). Also insulin
can diffuse readily out of the pores of the matrix. As a consequence
most capsule systems do not protect against the bioactive mole-
cules of the innate immune responses. The only effective strategy
up to now has been to keep activation of the immune system
as low as possible by applying alginates that lack any PAMP and
by applying perfectly smooth surfaces that do not allow for cell
adhesion and activation. It has been shown, however, that some
microcapsule designs might partially protect encapsulated cells by
interfering with diffusion kinetics of cytokines and chemokines
(de Vos and Marchetti, 2002; de Vos et al., 2006b; Nafea et al.,
2011). The final effect of the cytokines depends on their com-
bined presence (de Vos and Marchetti, 2002). When studying the
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Table 1 | Human homodimeric toll-like receptors, PAMPs, and DAMPs
that can be recognized by the differentTLRs (Fritz and Girardin, 2005;
Piccinini and Midwood, 2010; Basith et al., 2011; Rosin and Okusa,
2011; Liu and Ji, 2014).
TLR Ligating pathogen-
associated molecular
patterns (PAMPs)
Ligating damage-
associated molecular
patterns (DAMPs)
TLR1 Triacy lipopeptides β(-defensin-3
Soluble factors
TLR2 Zymosan HMGB1
Lipoteichoic acid HSPs
Lipoproteins Monosodium uric acid
Lipopeptides Hyaluronan
Peptidoglycan Biglycan
Bacterial porines Versican
Viric hemagglutinin
Glycolipids
Glycoinositol phospholipids
TLR3 dsRNA mRNA
TLR4 Lipopolysaccharides HMGB1
Taxol HSPs
Viral proteins Monosodium uric acid
Defensins
Lactoferrin
Hyaluronan
Biglycan
Fibrinogen
Heparan sulfate
Fibronectin extra domain A
Envelope proteins
TLR5 Bacterial flagellin Unknown
TLR6 Diacyl lipopeptides Unknown
Zymosan
Lipoteichoic acid
Phenol-soluble modulin
TLR7 ssRNA Cathelicidins
Imidazoquinoline
Loxoribine
TLR8 ssRNA ssRNA
Antiphospholipid antibodies
TLR9 Unmethylated CpG DNA HMGB1
DNA
Cathelicidins
IgG-chromatin complexes
TLR11 Uropathogenic bacteria Unknown
Profiling-like molecule
effects of the cytotoxic cocktail IL1-beta, TNF-alpha, and IFN-
gamma, it has been shown that when the capsule network is dense,
diffusion might be hampered, and partial protection might occur
(de Vos et al., 2003). Diffusion of solutes through alginate does
not only depend on the molecular weight of the molecule but
also on the three-dimensional structure, the factor of gyration,
and their charge density (Wee and Gombotz, 1998; de Vos et al.,
2006b). TNF-alpha is a 50 kDa trimeric molecule that does not dif-
fuse through the majority of microcapsule systems. Some capsule
types containing an in-homogeneous core have even been shown
to interfere with the diffusion of even smaller cytokines such as
IL-1beta (17.5 kDa) (Kulseng et al., 1997). Applying or adapting
the current microencapsulation systems might reduce cytotoxicity
by innate immune effector molecules.
HOMOGENEOUS AND IN-HOMOGENEOUS CORE CAPSULES
Microcapsules can be prepared with a homogeneous or an in-
homogeneous core. Homogeneous beads have a similar if not
identical concentration of alginate throughout the bead while non-
homogeneous beads typically have a higher alginate concentration
in the periphery and a lower concentration at the center of the bead
(Figure 8) (Qi et al., 2008). In-homogeneous alginate gels can
be produced by manipulating the diffusion of the alginate mole-
cules in the bead. This can be done by substituting the ions in the
gelling solution for iso-osmolites such as mannitol. The gelling
solution should have a low divalent cation concentration. What
subsequently will happen is that the alginate molecules will diffuse
toward the surface of the bead in order to compete for the scarce
divalent cations. The final consequence is a higher concentration
of alginate-polymers on the surface and a lower concentration in
the core. By lowering the cation concentration or increasing the
polymer concentration a gradual increase of the alginate concen-
tration at the rim of the capsule can be achieved (Mørch et al.,
2006; Qi et al., 2008). This approach can be applied to manip-
ulate the permeability properties of the capsules (Uludag et al.,
2000) and might be an effective tool to modulate the diffusion of
cytokines into the network.
This elegant method has been applied (Qi et al., 2008; Safley
et al., 2008) but has in addition to advantages also disadvantages.
During formation of in-homogeneous gels, osmotic pressure is
pushing the envelope tissue toward the rim of the capsules. This
holds two risks. The first is that during this process significant
shear forces are being put on the tissue. This may lead to fracture
of the islets and loss of function. The second risk is the increased
chance on protrusion of cells. The distribution of cells throughout
a capsule is determined by chance. When a capsule with a radius
of 500µm is divided in zones of 100µm, it can be calculated that
the chance that a cell will end up in one of the outer rims is high
(Figure 9). This is also confirmed by experimental studies (de Vos
et al., 1994; Del Guerra et al., 2001). This implies that the cells will
be pulled during the process of gel-formation toward the edge and
can even protrude from the capsules. When using this method, it
is advisable to apply assays to detect and/or remove capsules with
protruding cells (de Vos et al., 1996).
Although a very elegant method, it still remains to be deter-
mined whether this system composed of alginate only can provide
sufficient protection against the complex and inevitable activa-
tion of the innate and adaptive immune system. Especially, we
have doubts whether the permeability and diffusion character-
istics can be manipulated as such that protection is achieved
against the harsh xenogeneic responses. To the best of our
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knowledge, there are no efficacy studies available of this system
in non-immunosuppressed recipients.
BARIUM BEADS
Homogeneous gels are still the most commonly applied form of
gels in microcapsules. They have been applied in combination with
different types of divalent cations (Safley et al., 2008). A popular
one step system has been alginate-microcapsules gelled with bar-
ium. The microcapsules are characterized by a high mechanical
stability (Tam et al., 2011a) and are easy to produce without many
laborious complicated technological tools. The gel is formed after
cross-linking of barium in solution with carboxyl groups of M-
M and G-G chains (Zimmermann et al., 2005). Alginates with a
FIGURE 8 | Alginate gradient in in-homogeneous alginate-matrixes
(A) and in homogeneous capsules (B). In in-homogeneous capsules, the
concentration of alginates decrease gradually toward the center of the
capsule while in the homogeneous capsule the alginate concentration is
constant.
high-G-content are preferred as these alginates bind barium to
a higher extent than high-M alginates. It has been shown that
barium-alginate encapsulated islets can restore normoglycemia in
type 1 diabetic NOD mice for periods over 340 days (Duvivier-
Kali et al., 2001). When these allografts were explanted, it was
found that they lacked fibrotic overgrowth, and that islets in the
capsules had a preserved secretory function (Duvivier-Kali et al.,
2001). These results were not as successful when allografting was
performed in rats, where the normoglycemia lasted not more than
12 weeks and parameters, such as C-peptide release were decreased
(Omer et al., 2005).
When applying barium-beads for immunoprotection, it is
mandatory to control a number of items. Barium can be toxic
if present in high doses (Krishnamurthy and Gimi, 2011). It is
associated with hypertension and renal toxicity (Mørch et al.,
2012). It should be carefully controlled and documented that all
non-bound barium is removed from the beads before implan-
tation is considered. Also, the tissue in the capsule may suffer
from barium toxicity. Gelation times should be as short as pos-
sible during cell encapsulation to avoid inhibition of potassium
channels by barium in the encapsulated cells leading to cellular
death (Zimmermann et al., 2005).
There is debate whether barium beads can protect against
xenoresponses (Vaithilingam et al., 2011). The only way to reduce
the permeability of barium beads is by increasing the alginate
concentration and by using somewhat smaller alginate molecules
(Mørch et al., 2006). This all can be done until a certain limit.
When too high concentrations of alginate are applied, cells will
be affected due to mechanotransduction (Huang et al., 2012).
Mechanotransduction is a process in which cells sense that the
stiffness of their surrounding is above a certain critical threshold
(Orr et al., 2006). This leads to disturbance of cellular processes
with cell-death as the final consequence. It is not sufficiently stud-
ied to which concentration the system can be build and stay safely
under the mechanotransduction limit. It is, therefore, also not
known what the permeability limit of barium-beads is.
FIGURE 9 |The probability that islets are in the periphery of the capsules is higher than ending up in the center. This is even more pronounced in
in-homogenous alginate capsules as osmotic forces associated with movement of the alginate-polymers toward the surface induces a shift of the islets toward
the periphery.
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POLYAMINOACID-ALGINATE CAPSULES
The most commonly applied microencapsulation system is still
the alginate-polyaminoacid method. With this technique, an
immunoprotective and stabilizing membrane composed of a
polyaminoacid is built on the surface of an alginate bead. This
has been done on both homogeneous and in-homogeneous algi-
nate gels (Safley et al., 2008). An advantage of this system is that
it is versatile and allows for easy adjustment of the permeability
when for example the requirements are different for diverse tissues
such as for allogeneic and xenogeneic tissue.
Among the most common applied polyaminoacid are poly-
d-lysine (PDL), poly (ethylene glycol) (PEG), poly-l-ornithine
(PLO), and poly-l-lysine (PLL), as well as diblock copolymers of
PEG and PLL (Ponce et al., 2006). They have different properties
that make them more or less appropriate for certain applica-
tions. Some groups prefer PLO coating as it is known to reduce
the swelling and to increase the mechanical strength of alginate-
microcapsules restricting diffusion of higher molecular weight
molecules (Ponce et al., 2006). Others prefer PEG polymers to
prevent potential protein adsorption on the surface of the capsules
(Spasojevic et al., 2014). After three decades of research, there is
still debate, however, on which polymer is most optimal to build
an immunoprotective membrane. It should be noted that, just as
with the choice of the core material of the capsules, there are many
options, but only one polymer has been sufficiently studied to
allow safe application as will be outlined below.
A principle item that is missing in research on selection of ade-
quate polyamino acids for reduction of permeability of microcap-
sules is mechanistic insight in how the molecules bind to alginate.
This is extremely important as will be outlined for PLL. For many
years, PLL was out of favor by researchers. The reason was several
reports (Strand et al., 2001; Bünger et al., 2003) that described
strong inflammatory responses against PLL membranes (Orive
et al., 2006). When these reports are critically reviewed, it has to
be concluded that the researchers were not taking into account the
requirements for adequate PLL binding. Unbound PLL is cyto-
toxic and will have induced immune responses (Juste et al., 2005).
To allow PLL binding, it is mandatory after gel-formation in the
calcium-solution, to wash the beads with buffer with a low amount
of calcium and high amounts of sodium. This step is required to
extract calcium from the surface of the beads, which will subse-
quently be substituted by sodium. Sodium has a lower affinity for
the alginate than PLL. The PLL, which is subsequently added, is
binding to constitutive alginate molecules in a highly cooperative
manner to form a strong, rigid membrane with the G-M mole-
cules at the surface. This requires the binding of PLL with alginate
in a superhelical core and beta-sheets (Figure 10). This process
can be easily followed by Fourier-transform infrared spectroscopy
(FT-IR) that has become an indispensable tool in understand-
ing the interaction of polyamino acids on the capsule surface.
The degree of cross-linking determines not only the mechani-
cal stability and permeability of the membrane (van Hoogmoed
et al., 2003) but also the biocompatibility. When PLL is not forced
into the above-mentioned conformations, it will lead to strong
inflammatory responses.
Unfortunately only the requirements for PLL binding to
alginate-surfaces have been studied in sufficient detail to design
a reproducible protocol. For other used molecules such as PLO
(Calafiore, 2003), this has not been done as extensively. It is
unknown to which alginate-polymer(s), the other polymers bind
and in what chemical conformation they have to be to provide
biocompatibility. It is impossible, therefore, to recommend a type
of alginate for these polyamino acids. This was shown recently
with the combination of alginate and PLL. In a comparison study
of the in vivo behavior of a series of alginate-PLL capsules that
differed only 10% in G-content, we observed strong inflammatory
responses against one of the alginate-PLL membranes. This was
due to detachment of the PLL with the alginate that did not con-
tain sufficient amounts of G-M sequences required for persistent
binding (de Vos et al., 2012).
To overcome biocompatibility issues with polyamino acids,
some have chosen to apply an alternative strategy. They apply mul-
tilayer capsules in which the polyamino acid membrane is covered
with an additional biocompatible alginate layer (de Haan et al.,
2006). The polyamino acid is still used to reduce the permeability
but its binding conformation has become less critical as the layer is
not in direct contact with the host. Another strategy,which is devel-
oped by our own laboratory, is the application of diblock copoly-
mers (Spasojevic et al., 2014). Diblock copolymers are molecules
that are composed of two types of polymers that have different
beneficial properties for the capsules. We tested and applied dif-
ferent types of PEG-b-PLL diblock copolymers. Binding of these
copolymers was achieved through the ionic interactions between
the positively charged PLL block and the negatively charged algi-
nate. The other block, polyethylene glycol (PEG), should provide
a biocompatible protecting layer on the surface of the capsules.
Binding of the copolymer and the presence of the PEG blocks on
the surface of the capsules was demonstrated in our previous study
through the fluorescence labeling of methoxy end-group of PEG
(Spasojevic et al., 2014). In vivo safety studies are in progress but
the hope is that this concept may lead to more reproducible and
less laborious procedures to reduce the permeability of alginate
gels without interfering with biocompatibility.
In spite of the challenges that have to be met, the proof of
principle of the alginate-polyamino acid system has been pro-
vided in both allogeneic and xenogeneic combinations and it
has even entered the clinic (Calafiore et al., 2006b; Elliott et al.,
2007). Calafiore et al. used microencapsulated pancreatic islets
allografts in non-immunosuppressed patients with type 1 dia-
betes (Calafiore et al., 2006a,b). The grafts showed acceptable
biocompatibility. However, insulin independence was not achieved
as the authors were only allowed to use sub-optimal islet doses
(Calafiore et al., 2006b). Also in rodents and dogs successes has
been reported (Soon-Shiong et al., 1992; Tatarkiewicz et al., 2001).
In non-human primates, the results are less favorable (He et al.,
2013) but this might be due to differences in the immune system
of the non-human primates as will be outlined in the next section.
ARE PRIMATE STUDIES PREDICTABLE FOR HUMANS?
During recent years, there was a tendency to consider non-human
primate transplantation studies as the ultimate proof for effi-
cacy in humans (Anderson and Kirk, 2013; He et al., 2013).
This reasoning is supported by arguments of the FDA (Merkel
and Halperin, 2014) because of the assumption of similarities in
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FIGURE 10 | Structure of alginate-poly-L-lysine capsules. The
system is composed of two layers and not of three layers as wrongly
stated in many papers. The core of the capsule is composed of a matrix
of alginate and calcium in which the islets are entrapped. The second
layer is obtained after incubation of the calcium bead in sodium rich
solutions to form a sodium-alginate complex at the surface. Sodium can
be substituted by poly-L-lysine (PLL) to form a complex alginate-PLL-
alginate (APA). The PLL-alginate layer can take three different structures
by intramolecular hydrogen binding, (i) random coil formation between
alginate and PLL, (ii) α-helicoidal structure between amide groups of
PLL, and (iii) antiparallel β-sheet structure between amide groups
of PLL.
immune responses between humans and non-human primates
(Collins and Jones, 1978; Mezey et al., 1983; Vaithilingam and
Tuch, 2011). Despite absence of scientific proof and meeting
many ethical issues, the believers considered responses in non-
human primates to be analogous to that in humans (Anderson
and Kirk, 2013). To our opinion, this is a major misassumption.
As will be outlined below, there are pertinent immunological dif-
ferences between non-human primates and humans making the
non-human primate, an inadequate model for human responses
against encapsulated grafts. Immune responses may occur in non-
human primates but will not occur in humans and specific innate
responses not present in non-human primates may happen in
humans.
Immunological differences are considered to be the reason
for early mortality rates and life span rate differences between
humans and non-human primates such as chimpanzees (Finch,
2010). Humans differ from chimpanzees by low mortality rates in
both the juvenile and adult ages, and by the later onset of mor-
tality rate acceleration, usually by chronic degenerative diseases
(Finch, 2010). For wild chimpanzees, an early mortality rate of
20% per year in infancy is normal with a decrease to about 3.5%
per year in pre-adult ages. Infections play a major role in the high
chimpanzee mortality rates. The life expectancy at birth of a chim-
panzee is about 13 years, whereas animals that reach adulthood
have about 15 years of further life (Finch, 2010). This is very dif-
ferent in humans. Even in areas with limited access to medicine,
life expectation after birth is much longer and the high early age
mortality declines to a minimum at the approach of adulthood
(Finch, 2010). There is consensus that this species difference in
mortality rate and life span is due to differences in their immune
system that were developed more than a million years ago (Finch,
2010; Anderson and Kirk, 2013).
Finch (2010) has done basic research in differences between
humans and non-human primates innate and adaptive immune
responses. Finch was interested in the variations in immune-genes
that might explain the early differences in mortality rates between
non-human primates and humans. To this end, Finch performed
a stepwise comparison between chimpanzee and human-specific
immunological genes and did some important discoveries. The
most remarkable difference was in the composition of apolipopro-
tein E (ApoE) genes. This important gene is involved in metabo-
lism of lipids and in regulating innate immune responses. There
are three uniquely human ApoE alleles, of which ApoE e4 and
ApoE e3 are the most prevalent (Schaffer et al., 2014). The ApoE e4
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differs in several critical amino acids from the chimpanzee equiv-
alent. It is the most relevant gene for the current discussion as it
is responsible for boosting the human innate immune response,
which is diminished in non-human primates relative to humans
(Finch, 2010). ApoE e4 induces the acute innate response and
initiates the production of important innate immune cytokines
such as IL-6 and TNF-α (Vitek et al., 2009). Evolutionary, this
gave humans the benefit to better fight harmful intruders that
they ingested in food and encountered in their surroundings. This
difference in innate immunity is considered to be a major factor
in the difference in mortality rates in the juvenile and adult age
classes between humans and chimpanzees (Barreiro et al., 2010).
Also, this is pertinent when considering non-human primates as
a relevant immunological model for humans since mimicking the
human innate immune responses is a key in studies predicting the
efficacy of encapsulated grafts in humans.
Besides differences in activity of the innate immune system,
there are more immunological differences between humans and
non-human primates that are relevant for the discussion on the
adequacy of non-human primates as model for humans in our
type of research. Humans lack for example specific genes or have
specific polymorphisms making them incapable to perform some
specific immunological responses. Major differences have been
found in the major histocompatibility complex (MHC) (Finch,
2010). The MHC system is important for both innate and adap-
tive immune responses. An important species difference is the loss
of polymorphisms in class IA and B genes in humans. This implies
a class-specific loss of variation and therefore a selective elimina-
tion of responses against specific families of epitopes (de Groot
et al., 2008). Also a pertinent difference in PRRs has been reported
(Brinkworth et al., 2012). Human CD4+ T cells have low expres-
sion of Siglecs relative to chimpanzees (Nguyen et al., 2006). The
Siglec lectin family of proteins (Ig superfamily) is involved in T-cell
receptor (TCR) interactions and is implicated in the much milder
chimpanzee symptoms of HIV-1 and hepatitis B or C (Bibollet-
Ruche et al., 2008) infections due to more specific responses. This
illustrates that non-human primates may respond differently and
sometimes more rigorously against antigens than humans.
PRE-CLINICAL MODELS
The foregoing obviously calls for suggestions for better animal
models. The answer is simple. There is not a single step model that
predicts efficacy of encapsulated grafts in humans. Technologies
have emerged that has brought this research field into a next step
were animal studies and ex vivo studies are combined to predict
efficacy in humans. A first step is the need for animal models and
ex vivo systems mimicking human innate responses and avoiding
harsh innate immune responses is a key in the success of encapsu-
lated islets in humans. Although abandoned by some (Anderson
and Kirk, 2013; He et al., 2013) experimental animals such as mice
and rats have a more developed innate immune response than
non-human primates and are therefore more appropriate. Trans-
genic mice are available that resemble human innate responses
as close as it can get. There are TRapoE4 mice available that
have near identical human IL-6 and TNFα responses (Vitek et al.,
2009). Also, technology platforms are under development contain-
ing human PRRs giving insight in how these sensors of the human
immune system will react on encapsulated cell systems (Paredes-
Juarez et al., 2013, 2014). Another advance and to our opinion
mandatory research item is that some groups combine the fore-
going studies with mimicking protein adsorption processes that
occur in humans (de Haan et al., 2011; Rokstad et al., 2011).
Protein adsorption to biomaterial surfaces is assumed to be the
major cause of species differences (Vaithilingam and Tuch, 2011)
in foreign body responses. It was shown by our group that the
adsorption and changes at the capsule surface are highly depen-
dent on the polymer applied and can be avoided (Spasojevic et al.,
2014). This combined approach with a proof of principle study in
any larger mammal with a well-developed innate immune system
will be our preferred approach to come to a predictive outcome in
humans.
FUTURE CONSIDERATION
As outlined in the preceding sections, there are many choices when
considering alginate-based microcapsules for immunoprotection
of pancreatic islets. Most of the systems mentioned above have
shown some efficacy in allogeneic settings but in xenogeneic set-
tings not many successful studies are available (Murua et al., 2009).
This might not always be the consequence of immunological
issues. Incompatibility in metabolism may also be a contributing
factor. It has been shown, for example, that rat islets maintain their
metabolism when transplanted in mice (Bobzien et al., 1983). This
may lead to rapid exhaustion when the recipient has a higher meta-
bolic demand than the donor. Another or combined explanation
is that the prerequisites of the membrane are far more strict with
xenografts than with allografts. Xenografts may provoke stronger
responses by leaking immunoreactive epitopes, such as galacto-
syl residues, that may react with pre-existing, naturally occur-
ring (anti-Gal) and non-Gal IgM antibodies with strong innate
responses as a consequence. Currently, it is unknown whether the
membranes can provide sufficient protection against the cytokines
and deleterious bioactive molecules that are produced during
xenoresponses (de Vos et al., 2014). It has been shown, however
(de Vos and Marchetti, 2002), that human cytokines are not very
effective in killing xenogeneic tissue due to structural differences
in cytokine and receptor composition between humans and ani-
mals (Brinkworth et al., 2012). It is imperative for the future of
encapsulation to determine, which of the above-mentioned factors
contribute to the success or failure of immunoprotected xenografts
and which sources have the capacity to maintain long-term graft
function in humans.
Irrespective of the islet-source or system, it is mandatory to pro-
duce high-quality alginates that lack pro-inflammatory molecules
such as PAMPs. PAMPs are introduced in alginates at different
stages of production and can even be included during purification
due to the application of chemicals or instruments that contain
PAMPs (Paredes-Juarez et al., 2014). As outlined above all com-
mercial alginates, even those that are marketed as “ultra-pure”
and recommended for clinical application, do contain PAMPs and
do initiate inflammatory responses (Paredes-Juarez et al., 2014).
This is to our opinion, a major obstacle for clinical application
of encapsulated islets. The ease of removal of PAMPs is in our
hands alginate-type dependent. Removal of PAMPs from high-G
alginates is more difficult than from intermediate-G sources. This
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is probably due to the fact that high-G alginate solutions have
higher viscosities, which makes the washing steps during purifica-
tion often less efficacious. Chemical extraction methods are most
successful as well as dialysis against endotoxin free water. Com-
binations of these technologies as well as specific precipitation
methods are probably required to remove PAMPs from alginate
sources that are harsh to purify.
Stress signals released by microencapsulated islets themselves
have not gained much attention in the success and failure of encap-
sulated islet grafts. As cell-death induced by necrosis is a major
player in the failure of islet-grafts, it is plausible that DAMPs do
contribute to the magnitude of the innate responses and failure
of the grafts. A conceivable approach to overcome these types of
issues, is the use of smaller islets (i.e., smaller than 150µm) that
can manage the relative low oxygen tensions without significant
loss of cells by necrosis (Colton, 2014). Other strategies might be
to design membranes that retain DAMPS or inclusion of phar-
macological drugs such as necrostatin-1 that inhibits necrosis of
β-cells (Tamura et al., 2011).
The above and most of the papers addressing species-specific
efficacy of encapsulation systems discuss predominantly immuno-
logical issues. An overlooked but pertinent issue when comparing
efficacy of encapsulation systems is the different requirements for
mechanical stability, the capsules have to meet. It is unknown,
for example, how rigid and elastic capsules should be in larger
mammals. In rats, we know that capsules that can withstand a
force of 8 g can survive up to 2 years in rats, i.e., the lifespan of
rats. In pigs, however, the shear forces are much higher and more
capsules were having imperfections on the membrane and con-
tained immune-cells. This illustrates that, going from one species
to another, adaptations have to be made in the mechanic-physic
properties of the capsules and that caution should be taken to inter-
pret the host-reactions as species-specific responses against the
capsules. In our experience going from one organism to another
requires significant adaptations of the system before any scien-
tifically sound comparison in immune responses can be made
(Scharp and Marchetti, 2014). Unfortunately, these types of adap-
tations are rarely done but are, to our opinion, mandatory now that
encapsulation devices are coming closer to clinical application.
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